Gut Microbiota-Derived Butyrate Induces Trained Immunity in Intestinal Macrophages to Potentiate Antitumor Immunity
DOI:
https://doi.org/10.63808/bm.v2i1.523Keywords:
Gut microbiota, Butyrate, Trained immunity, Intestinal macrophages, Antitumor immunityAbstract
The gut microbiota metabolite butyrate plays an important role in maintaining intestinal immune homeostasis, but it’s still unclear whether it can induce trained immunity in intestinal macrophages and thus affect anti-tumor immune responses. This study aimed to investigate the ability of butyrate to induce trained immunity in intestinal macrophages and its function and mechanism in anti-tumor immunity. We used an MC38 colorectal cancer mouse model, combined with strategies such as broad-spectrum antibiotics to clear gut microbiota, butyrate supplementation, colonization with butyrate-producing bacteria, macrophage depletion, and adoptive transfer. In vitro, we pretreated bone marrow-derived macrophages and intestinal lamina propria macrophages with butyrate, allowed them to rest, then gave a secondary stimulus to assess cytokine secretion, phagocytic function, metabolic reprogramming, and epigenetic modifications. RNA-seq, ATAC-seq, and CUT&Tag were used to analyze the molecular mechanisms. Butyrate pretreatment induced trained immunity in macrophages, showing significantly enhanced TNF-α, IL-6, and IL-1β secretion after a second stimulus, increased glycolysis, and enriched H3K4me3 modifications at key inflammatory gene promoters. Mechanistically, butyrate drives epigenetic reprogramming and metabolic remodeling in macrophages by inhibiting histone deacetylase activity and activating the GPR43-mTOR-HIF-1α signaling axis. In tumor-bearing mice, butyrate supplementation or colonization with butyrate-producing bacteria significantly enhanced the anti-tumor phenotype of intestinal macrophages, promoted CD8⁺ T cell infiltration and activation in tumors, and suppressed tumor growth; this effect was markedly weakened in mice with macrophage-specific trained immunity deficiency. Gut microbiota-derived butyrate induces trained immunity in intestinal macrophages, reshapes the tumor immune microenvironment, and enhances anti-tumor immune responses, offering new ideas for tumor immunotherapy targeting the microbiota metabolite-macrophage trained immunity axis.
References
[1] Arpaia, N., Campbell, C., Fan, X., et al. (2013). Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature, 504(7480), 451-455. https://doi.org/10.1038/nature12726
[2] Arts, R. J., Novakovic, B., Ter Horst, R., et al. (2016). Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity. Cell Metab, 24(6), 807-819. https://doi.org/10.1016/j.cmet.2016.10.008
[3] Belkaid, Y., & Hand, T. W. (2014). Role of the microbiota in immunity and inflammation. Cell, 157(1), 121-141. https://doi.org/10.1016/j.cell.2014.03.011
[4] Chang, P. V., Hao, L., Offermanns, S., & Medzhitov, R. (2014). The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci U S A, 111(6), 2247-2252. https://doi.org/10.1073/pnas.1322269111
[5] Cheng, S. C., Quintin, J., Cramer, R. A., et al. (2014). mTOR- and HIF-1α–mediated aerobic glycolysis as metabolic basis for trained immunity. Science, 345(6204), 1250684. https://doi.org/10.1126/science.1250684
[6] Furusawa, Y., Obata, Y., Fukuda, S., et al. (2013). Commensal microbe-derived butyrate induces differentiation of colonic regulatory T cells. Nature, 504(7480), 446-450. https://doi.org/10.1038/nature12721
[7] Honda, K., & Littman, D. R. (2016). The microbiota in adaptive immune homeostasis and disease. Nature, 535(7610), 75-84. https://doi.org/10.1038/nature18848
[8] Kalafati, L., Kourtzelis, I., Schulte-Schrepping, J., et al. (2020). Innate immune training of granulopoiesis promotes anti-tumor activity. Cell, 183(3), 771-785.e12. https://doi.org/10.1016/j.cell.2020.09.058
[9] Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016). From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. Cell, 165(6), 1332-1345. https://doi.org/10.1016/j.cell.2016.05.041
[10] Liu, G. (2025). Mechanisms of gut microbiota regulating tumor immune response and their potential for clinical translation. Immuno-Oncology, 1(1), 8-13. http://dx.doi.org/10.66106/mzabb7.20250102
[11] Liu, G., Wang, J., & Zhu, J. (2026a). Explainable spatial AI analyzes tumor-immune interactions to predict immunotherapy outcomes and identify new targets. Intelligent & Human Futures, 2(3), 510. http://dx.doi.org/10.63808/ihf.v2i3.510
[12] Liu, G., Wang, J., & Zhu, J. (2026b). Using multimodal foundational models to predict neoantigen immunogenicity and vaccine effectiveness across different tumor types. Global Health Care, 2(3), 498. http://dx.doi.org/10.63808/ghc.v2i3.498
[13] Louis, P., Hold, G. L., & Flint, H. J. (2014). The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol, 12(10), 661-672. https://doi.org/10.1038/nrmicro3344
[14] Maslowski, K. M., Vieira, A. T., Ng, A., et al. (2009). Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature, 461(7268), 1282-1286. https://doi.org/10.1038/nature08530
[15] Matson, V., Fessler, J., Bao, R., et al. (2018). The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science, 359(6371), 104-108. https://doi.org/10.1126/science.aao3290
[16] Mitroulis, I., Ruppova, K., Wang, B., et al. (2018). Modulation of myelopoiesis progenitors is an integral component of trained immunity. Cell, 172(1-2), 147-161.e12. https://doi.org/10.1016/j.cell.2017.11.034
[17] Netea, M. G., Domínguez-Andrés, J., Barreiro, L. B., et al. (2020). Defining trained immunity and its role in health and disease. Nat Rev Immunol, 20(6), 375-388. https://doi.org/10.1038/s41577-020-0285-6
[18] Netea, M. G., Joosten, L. A., Latz, E., et al. (2016). Trained immunity: A program of innate immune memory in health and disease. Science, 352(6284), aaf1098. https://doi.org/10.1126/science.aaf1098
[19] Noy, R., & Pollard, J. W. (2014). Tumor-associated macrophages: from mechanisms to therapy. Immunity, 41(1), 49-61. https://doi.org/10.1016/j.immuni.2014.06.010
[20] Routy, B., Le Chatelier, E., Derosa, L., et al. (2018). Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science, 359(6371), 91-97. https://doi.org/10.1126/science.aan3706
[21] Schulthess, J., Pandey, S., Capitani, M., et al. (2019). The short chain fatty acid butyrate imprints an antimicrobial program in macrophages. Immunity, 50(2), 432-445.e7. https://doi.org/10.1016/j.immuni.2018.12.018
[22] Singh, N., Gurav, A., Sivaprakasam, S., et al. (2014). Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity, 40(1), 128-139. https://doi.org/10.1016/j.immuni.2013.12.007
[23] Smith, P. M., Howitt, M. R., Panikov, N., et al. (2013). The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science, 341(6145), 569-573. https://doi.org/10.1126/science.1241165
[24] Vétizou, M., Pitt, J. M., Daillère, R., et al. (2015). Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science, 350(6264), 1079-1084. https://doi.org/10.1126/science.aad1329
[25] Zitvogel, L., Galluzzi, L., Viaud, S., et al. (2015). Cancer and the gut microbiota: an unexpected link. Sci Transl Med, 7(271), 271ps1. https://doi.org/10.1126/scitranslmed.3010473
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Gang Liu, Jia Wang, Liqiang An
This work is licensed under a Creative Commons Attribution 4.0 International License.